The survey, conducted by Ai-powered study matching company TrialJectory, indicates more patients than ever are interested in clinical trial participation post-pandemic.
The research collaboration is aimed at studying disparities in care with a focus on multiple myeloma, a cancer disproportionately affecting Black patients.
Medable will collaborate with Aural Analytics in an initiative funded by the NIH’s seven-year Beau Biden Cancer Moonshot research and development program.
The US federal agency has released a document designed to help clinical trial teams obtain effective, efficient data from patients in their cancer research.
The University of Kansas Cancer Center has joined with trial tech provider Complion to develop a shared investigator platform for use in a range of studies.
The pharma firm plans to use the StudyTeam platform to accelerate development, ease site burdens and improve patient matching for breast cancer studies.
The therapeutic has been approved as an adjuvant treatment for varieties of esophageal cancers in patients who have received neoadjuvant chemoradiotherapy.
A robust research and innovation ecosystem makes Italy an attractive life sciences hotspot, according to a post from an Italian trade delegation at Bio Digital 2021.
The company reportedly will utilize the investment funding to expand its research platform, and to advance six of its preclinical therapeutic programs.
A leader from clinical-stage pharma firm NuCana shares promising results for its ProTides therapies and hopes the drugs can elevate outcomes for patients.
A leader from oncology trial insights and analysis specialist Inteliquet discusses how cancer studies can recover after the impact of the global pandemic.
An advanced cancer detection platform from C2i Genomics (reportedly capable of spotting miniscule traces of the disease) recently landed $100m in funding.
One Health’s FidoCure is using genomics and AI technology to develop precision oncological treatments, and the work is benefiting human cancer research.
The two companies will work together to evaluate the combination of SLC-391 and Keytruda in treating patients with advanced non-small cell lung cancer.
The results of a recent Phase III study show caregivers can gauge by individual age, functional status to adapt treatment approaches to specific patients.
William Gholston, with the Tampa Bay Buccaneers football team, is donating to the Moffitt Cancer Center to fund research into cancer treatment disparities.
The company’s medical imaging technology and other eClinical solutions reportedly played a part in half of the treatments to receive the FDA designation.
The company’s cancer drug, devimistat, has received orphan status from the agency for treating clear-cell sarcoma, pancreatic cancer, and other diseases.
According to one New Yorker, encountering the AI-assisted TrialJectory technology helped cut through the uncertainty to provide information and solutions.
The precision medicine firm is joining with the oncology network in an effort to help improve treatment options and outcomes for cancer patients worldwide.
The UK-based collaboration will include expertise across more than 40 types of cancer, with access to patients from more than 170 referring oncologists.
The pharmaceutical company shares details from an ongoing trial looking into the effectiveness of a pair of drugs on treating triple-negative breast cancer.
The FDA this week released a new draft guidance encouraging the inclusion of male patients in breast cancer clinical trials, the incidence of which has increased approximately 26% over the last 25 years.
Capital Health joins Kiyatec’s clinical trial to validate a patient-specific predictor test to improve response to cancer therapies for glioblastoma and anaplastic astrocytoma.
To further support Asia-Pacific oncology trials, NeoGenomics opens new Singapore-based pharma services laboratory in the same building as PPD Laboratories’ central lab.
Theralase taps an undisclosed trial management organization for the site selection of its multi-country bladder cancer study which aims to enroll 100 patients across 20 sites.
Syapse today announces a strategic collaboration with Pfizer through which it will generate insights from de-identified real-world data and advance oncology outcomes research.
Scientific advances and regulatory incentives are driving the use of genetics in drug development, though the industry’s ability to perform wide-scale testing has outpaced its understanding of the results, the misinterpretation of which can have “disastrous”...
Elligo expands its Research Ready network and adds its first oncology practice through a partnership with Austin Cancer Center, which is currently enrolling patients for breast cancer studies.
AG Mednet provides imaging services to Median Technologies in support of the company's portfolio of clinical trials, including "large programs" in China.
Belong.Life raises $14m as part of a Series B funding round with plans to expand its patient engagement platform, using and complementing Iqvia’s solutions “to transform patient engagement,” says Iqvia VP.
Saga Diagnostics AB secures venture-backed financing to advance its precision oncology genomics testing technology, which is being used to monitor patient responses in clinical trials, among other applications.
The global oncology market last year set several records, though the industry continues to struggle with long development timelines, which in 2018 averaged 10.5 years from patent filing to regulatory approval and launch, according to a recent Iqvia report.
Parexel today unveiled its Oncology Center of Excellence as well as a new “early advisory service” focused on study design, regulatory strategy, and market access.
